▁Introduction 10.375
: 6.515625
<0x0A> 3.95703125
M 4.5390625
el 3.822265625
an 3.658203125
oma 0.79150390625
, 2.951171875
▁a 2.03515625
▁form 2.568359375
▁of 0.005092620849609375
▁skin 0.140380859375
▁cancer 0.00555419921875
, 0.194580078125
▁has 2.888671875
▁experienced 6.77734375
▁significant 3.201171875
▁adv 2.06640625
anc 1.296875
ements 0.0002200603485107422
▁in 0.34423828125
▁treat 4.43359375
ments 0.006439208984375
▁in 2.0234375
▁recent 0.599609375
▁years 0.1651611328125
. 0.420166015625
▁Among 5.0234375
▁these 1.4892578125
▁adv 1.125
anc 0.12274169921875
ements 5.8770179748535156e-05
, 1.2314453125
▁imm 2.783203125
une 3.34765625
▁check 0.17236328125
point 0.0164794921875
▁in 0.2144775390625
hib 0.00022268295288085938
itors 0.1646728515625
▁and 4.203125
▁adj 6.68359375
uv 0.0208282470703125
ant 0.007030487060546875
▁ther 0.505859375
ap 0.61181640625
ies 0.00014984607696533203
▁have 0.52978515625
▁emer 3.6796875
ged 0.0003662109375
▁as 0.1368408203125
▁prom 2.513671875
ising 0.0007266998291015625
▁approaches 3.673828125
. 2.24609375
▁This 3.4609375
▁ess 8.6015625
ay 0.004154205322265625
▁expl 3.169921875
ores 0.006771087646484375
▁the 0.49560546875
▁potential 3.59765625
▁benefits 2.7734375
▁of 0.609375
▁these 1.548828125
▁treat 2.03125
ments 0.0001819133758544922
, 1.5517578125
▁their 2.6171875
▁imp 5.35546875
lications 0.046539306640625
▁for 0.4462890625
▁patients 2.140625
▁at 6.6484375
▁different 2.48828125
▁stages 0.31640625
▁of 0.07843017578125
▁mel 1.5478515625
an 0.0001024007797241211
oma 0.002964019775390625
, 0.498046875
▁and 0.127685546875
▁their 1.615234375
▁impact 3.298828125
▁on 0.091552734375
▁impro 5.83984375
ving 0.00020074844360351562
▁surv 2.3046875
ival 0.030792236328125
▁rates 0.93212890625
. 0.388671875
▁Furthermore 5.1171875
, 0.0025844573974609375
▁it 1.283203125
▁will 3.236328125
▁draw 7.1328125
▁on 1.2041015625
▁research 3.81640625
▁evidence 3.66015625
▁and 1.55078125
▁analyze 6.546875
▁the 0.93701171875
▁case 7.140625
▁of 2.2421875
▁Mr 7.9765625
. 0.1781005859375
▁B 3.87109375
▁as 4.38671875
▁an 1.162109375
▁illustr 1.96484375
ative 0.5703125
▁example 0.11566162109375
. 0.90380859375
<0x0A> 0.39794921875
Body 8.4765625
: 3.12890625
<0x0A> 1.671875
I 4.37890625
. 0.5537109375
▁Im 3.06640625
m 0.289794921875
une 0.01064300537109375
▁Check 0.26025390625
point 0.0238494873046875
▁In 0.03924560546875
hib 0.0005040168762207031
itors 0.07183837890625
: 2.63671875
<0x0A> 0.62451171875
A 2.125
. 0.1976318359375
▁Mechan 3.736328125
ism 0.343017578125
▁of 0.36767578125
▁Action 0.1524658203125
: 0.53759765625
<0x0A> 0.048858642578125
Im 3.384765625
m 0.09930419921875
une 0.016204833984375
▁check 0.08551025390625
point 0.05450439453125
▁in 0.0245361328125
hib 0.00036716461181640625
itors 0.0277099609375
, 2.556640625
▁such 2.00390625
▁as 0.0036754608154296875
▁p 1.609375
emb 0.0019245147705078125
rol 0.001865386962890625
iz 0.0020751953125
um 0.0023174285888671875
ab 0.00020694732666015625
▁and 1.21484375
▁n 0.061981201171875
iv 0.00160980224609375
ol 0.00040912628173828125
um 0.0007801055908203125
ab 0.0006432533264160156
, 0.054840087890625
▁aim 5.828125
▁to 0.039306640625
▁enh 5.30859375
ance 4.088878631591797e-05
▁the 0.343017578125
▁body 1.3984375
' 0.0096893310546875
s 0.00019538402557373047
▁imm 0.63525390625
une 0.01233673095703125
▁response 1.0537109375
▁against 1.5166015625
▁mel 1.6279296875
an 0.00023818016052246094
oma 0.0269012451171875
▁cells 1.8291015625
▁by 1.1943359375
▁blocking 1.2275390625
▁the 1.32421875
▁suppress 7.50390625
ive 0.1956787109375
▁signals 3.7578125
▁im 5.9453125
posed 1.39453125
▁by 0.271240234375
▁specific 3.412109375
▁imm 1.1552734375
une 0.036529541015625
▁check 0.1331787109375
points 0.54150390625
, 2.10546875
▁like 5.0859375
▁P 0.90625
D 0.0069580078125
- 0.190185546875
1 0.07037353515625
/ 2.62890625
PD 0.033233642578125
- 0.00370025634765625
L 0.005329132080078125
1 0.00835418701171875
▁and 1.201171875
▁CT 0.1456298828125
LA 0.0006737709045410156
- 0.11175537109375
4 0.0010995864868164062
. 0.228759765625
<0x0A> 2.001953125
B 1.02734375
. 0.0119781494140625
▁Effect 4.40625
iveness 1.3837890625
▁and 2.955078125
▁Long 6.1640625
- 0.08203125
term 1.205078125
▁Rem 6.609375
ission 0.1717529296875
: 0.27734375
<0x0A> 0.01113128662109375
Res 3.884765625
earch 0.006969451904296875
▁has 1.044921875
▁shown 0.46142578125
▁substantial 8.359375
▁promise 3.98828125
▁in 1.0771484375
▁imm 3.18359375
une 0.10308837890625
▁check 0.02410888671875
point 0.004833221435546875
▁in 0.052947998046875
hib 0.00017702579498291016
itors 0.28955078125
, 1.5419921875
▁leading 4.8515625
▁to 0.07562255859375
▁impress 4.359375
ive 0.003910064697265625
▁response 4.50390625
▁rates 0.06201171875
▁and 0.89990234375
▁dur 2.029296875
able 0.08270263671875
, 4.99609375
▁long 0.32275390625
- 0.00811767578125
term 0.08856201171875
▁rem 0.124755859375
ission 0.66259765625
▁in 1.173828125
▁patients 1.087890625
▁with 0.292724609375
▁advanced 1.291015625
▁mel 0.148681640625
an 6.818771362304688e-05
oma 0.01465606689453125
. 0.21923828125
▁C 5.7265625
lin 0.041534423828125
ical 0.01537322998046875
▁tri 0.363037109375
als 1.6927719116210938e-05
▁demonstrated 6.6796875
▁a 2.087890625
▁significant 2.74609375
▁surv 3.52734375
ival 0.00030040740966796875
▁advantage 1.1142578125
▁for 1.150390625
▁patients 0.29150390625
▁treated 1.052734375
▁with 0.00749969482421875
▁p 1.578125
emb 0.0026702880859375
rol 0.0002789497375488281
iz 0.0008211135864257812
um 0.0013456344604492188
ab 9.107589721679688e-05
▁and 1.466796875
▁n 0.243896484375
iv 0.001659393310546875
ol 0.00024008750915527344
um 0.0007252693176269531
ab 0.00017726421356201172
▁compared 1.2431640625
▁to 0.301513671875
▁traditional 5.31640625
▁ther 1.2578125
ap 0.149658203125
ies 1.1086463928222656e-05
. 0.9208984375
<0x0A> 0.87890625
C 0.61669921875
. 0.005847930908203125
▁Imp 3.56640625
lications 0.75
▁for 0.1614990234375
▁Pat 0.88330078125
ients 0.0299835205078125
▁at 1.2958984375
▁D 0.01654052734375
ifferent 0.0008025169372558594
▁St 0.0280609130859375
ages 8.177757263183594e-05
: 2.201171875
<0x0A> 0.003528594970703125
1 6.88671875
. 0.2308349609375
▁Advanced 3.501953125
▁Mel 1.34375
an 0.0001857280731201172
oma 0.004390716552734375
: 0.446044921875
▁Im 4.38671875
m 0.18798828125
une 0.002857208251953125
▁check 0.19287109375
point 0.0238189697265625
▁in 0.01397705078125
hib 0.00016832351684570312
itors 0.0360107421875
▁have 0.93359375
▁proven 3.35546875
▁particularly 4.08203125
▁effective 0.4765625
▁in 0.30712890625
▁patients 0.8955078125
▁with 0.21875
▁advanced 0.350341796875
▁or 4.77734375
▁met 0.0794677734375
ast 0.0004684925079345703
atic 0.0021915435791015625
▁mel 0.023681640625
an 3.24249267578125e-05
oma 0.004512786865234375
, 1.0830078125
▁ach 4.765625
ieving 6.92605972290039e-05
▁higher 5.76953125
▁response 0.57763671875
▁rates 0.0841064453125
▁and 0.27490234375
▁superior 6.33203125
▁overall 2.1640625
▁surv 0.06744384765625
ival 0.0033168792724609375
▁compared 1.2353515625
▁to 0.08319091796875
▁standard 2.0859375
▁treat 1.970703125
ments 0.00015592575073242188
. 0.22216796875
<0x0A> 0.62451171875
2 0.1539306640625
. 0.0019197463989257812
▁Early 2.611328125
- 1.7080078125
stage 0.57177734375
▁Mel 0.0775146484375
an 5.137920379638672e-05
oma 0.0007119178771972656
: 0.0218658447265625
▁Studies 4.93359375
▁are 6.80859375
▁under 1.6962890625
way 0.0233001708984375
▁to 0.0927734375
▁investigate 2.462890625
▁the 0.31298828125
▁potential 1.1767578125
▁role 3.025390625
▁of 0.040618896484375
▁imm 0.11419677734375
une 0.052978515625
▁check 0.01088714599609375
point 0.007572174072265625
▁in 0.00955963134765625
hib 1.6808509826660156e-05
itors 0.0182647705078125
▁in 0.0943603515625
▁adj 8.1015625
uv 0.00661468505859375
ant 0.0002510547637939453
▁ther 0.55517578125
apy 0.2418212890625
▁settings 5.5078125
, 0.95068359375
▁which 2.64453125
▁may 1.7607421875
▁improve 2.751953125
▁out 1.3798828125
comes 0.00368499755859375
▁and 3.0625
▁reduce 1.392578125
▁rec 4.11328125
urrence 0.267578125
▁rates 0.7255859375
▁in 0.830078125
▁patients 0.420654296875
▁with 0.31103515625
▁earlier 4.8671875
▁stages 1.671875
▁of 0.030242919921875
▁mel 0.1263427734375
an 2.110004425048828e-05
oma 0.0012178421020507812
. 0.08380126953125
<0x0A> 0.0654296875
II 2.3984375
. 0.00428009033203125
▁Ad 0.214111328125
j 0.00478363037109375
uv 0.0009303092956542969
ant 0.00015532970428466797
▁Ther 0.055206298828125
ap 0.2457275390625
ies 0.00013375282287597656
: 0.07659912109375
<0x0A> 0.00855255126953125
A 0.24560546875
. 0.00424957275390625
▁Com 5.359375
bin 0.2435302734375
ation 0.234619140625
▁Ther 0.487548828125
ap 0.38720703125
ies 6.246566772460938e-05
: 0.072021484375
<0x0A> 0.1741943359375
Com 1.34765625
bin 0.0024967193603515625
ations 3.943359375
▁of 0.038360595703125
▁imm 0.38818359375
une 0.03424072265625
▁check 0.0170440673828125
point 0.0021228790283203125
▁in 0.006572723388671875
hib 2.7418136596679688e-05
itors 0.0148162841796875
▁with 0.90234375
▁other 0.65234375
▁adj 3.46484375
uv 0.00194549560546875
ant 0.0068817138671875
▁ther 0.19091796875
ap 0.00635528564453125
ies 1.4662742614746094e-05
, 0.9794921875
▁such 0.1566162109375
▁as 0.0013971328735351562
▁target 2.724609375
ed 0.001728057861328125
▁ther 0.447509765625
ap 0.2666015625
ies 7.867813110351562e-06
▁or 2.091796875
▁radi 3.2578125
other 0.005611419677734375
apy 0.01493072509765625
, 0.0205230712890625
▁show 5.65625
▁potential 2.412109375
▁in 1.69140625
▁impro 0.57421875
ving 8.225440979003906e-06
▁treatment 3.16015625
▁out 0.1973876953125
comes 4.5180320739746094e-05
▁and 0.97607421875
▁prevent 4.73828125
ing 0.0293426513671875
▁tum 3.08203125
or 0.058837890625
▁re 1.98046875
lapse 0.0926513671875
. 0.298583984375
<0x0A> 0.27294921875
B 0.033172607421875
. 0.0008749961853027344
▁Effect 5.69140625
iveness 0.921875
▁in 2.708984375
▁Red 5.90234375
uc 0.02374267578125
ing 7.987022399902344e-06
▁Rec 1.17578125
urrence 0.0230865478515625
: 0.70751953125
<0x0A> 0.0080413818359375
C 2.98828125
lin 0.1422119140625
ical 0.0018720626831054688
▁tri 0.1593017578125
als 2.0265579223632812e-06
▁have 0.3447265625
▁illustrated 7.703125
▁the 1.1904296875
▁effect 1.9208984375
iveness 0.002689361572265625
▁of 0.047760009765625
▁adj 1.0810546875
uv 0.002101898193359375
ant 0.00028014183044433594
▁ther 0.393798828125
ap 0.1473388671875
ies 1.9431114196777344e-05
▁in 0.5966796875
▁significantly 4.3828125
▁reducing 0.110595703125
▁the 0.74853515625
▁risk 0.19287109375
▁of 0.0129241943359375
▁rec 1.1279296875
urrence 0.021942138671875
▁in 0.8193359375
▁patients 0.11895751953125
▁with 0.1292724609375
▁high 4.3203125
- 0.149169921875
ris 0.0280303955078125
k 1.6450881958007812e-05
▁mel 0.2393798828125
an 1.5735626220703125e-05
omas 3.455078125
▁after 4.11328125
▁surg 1.6435546875
ical 1.6767578125
▁removal 1.353515625
. 1.0751953125
<0x0A> 0.333251953125
C 1.533203125
. 0.1624755859375
▁Imp 0.578125
lications 0.01202392578125
▁for 0.0229644775390625
▁Pat 0.06475830078125
ients 0.0012197494506835938
▁at 0.10198974609375
▁D 0.006221771240234375
ifferent 8.118152618408203e-05
▁St 0.003665924072265625
ages 7.11679458618164e-05
: 0.0325927734375
<0x0A> 0.00608062744140625
1 0.43603515625
. 0.0015707015991210938
▁Inter 5.86328125
mediate 0.017364501953125
▁to 4.0
▁High 0.9951171875
- 0.28955078125
ris 0.39404296875
k 7.152557373046875e-05
▁Mel 0.179443359375
an 0.00011420249938964844
oma 0.262939453125
: 0.0322265625
▁Ad 2.08984375
j 0.006298065185546875
uv 0.000499725341796875
ant 0.0004944801330566406
▁ther 0.1588134765625
ap 0.1605224609375
ies 1.8358230590820312e-05
▁have 1.541015625
▁shown 1.056640625
▁prom 1.3203125
ising 7.081031799316406e-05
▁results 0.59228515625
▁in 0.1129150390625
▁impro 1.6630859375
ving 1.3113021850585938e-05
▁surv 1.69921875
ival 0.0007190704345703125
▁rates 0.5947265625
▁and 0.7275390625
▁prolong 6.046875
ing 0.004085540771484375
▁rem 2.69921875
ission 0.02374267578125
▁in 0.427001953125
▁patients 0.159423828125
▁at 2.482421875
▁intermediate 0.32177734375
▁to 0.8349609375
▁high 0.00399017333984375
- 0.2484130859375
ris 0.0016736984252929688
k 2.6226043701171875e-05
▁stages 3.09375
▁of 0.189208984375
▁mel 0.0292205810546875
an 3.159046173095703e-05
oma 0.0030460357666015625
, 1.91015625
▁reducing 3.330078125
▁the 0.1781005859375
▁ch 4.9375
ances 0.0005769729614257812
▁of 0.0195465087890625
▁rec 1.0068359375
urrence 0.0169219970703125
▁and 0.65087890625
▁disease 3.88671875
▁pro 0.28271484375
gression 0.00019252300262451172
. 0.1295166015625
<0x0A> 0.08929443359375
2 0.06781005859375
. 0.0012273788452148438
▁Low 1.1484375
- 0.049652099609375
ris 0.3759765625
k 2.3603439331054688e-05
▁Mel 0.027008056640625
an 5.412101745605469e-05
oma 0.0034122467041015625
: 0.01395416259765625
▁The 3.71875
▁role 2.490234375
▁of 0.025238037109375
▁adj 0.028411865234375
uv 0.0005908012390136719
ant 0.0001647472381591797
▁ther 0.03704833984375
ap 0.138916015625
ies 1.7404556274414062e-05
▁in 0.1634521484375
▁low 2.951171875
- 0.00991058349609375
ris 0.0285491943359375
k 1.2993812561035156e-05
▁mel 0.370849609375
an 5.9723854064941406e-05
oma 0.57666015625
▁is 0.9306640625
▁not 2.822265625
▁yet 0.9345703125
▁well 1.2685546875
- 1.0712890625
est 0.74951171875
ab 0.0004291534423828125
lished 0.0001093149185180664
. 1.09375
▁More 4.46484375
▁research 0.376708984375
▁is 0.117431640625
▁needed 0.26904296875
▁to 0.08331298828125
▁determine 1.142578125
▁their 1.802734375
▁potential 1.537109375
▁benefits 1.326171875
▁in 1.728515625
▁this 0.35693359375
▁patient 2.75390625
▁population 0.0987548828125
. 0.1507568359375
<0x0A> 0.042388916015625
III 0.80419921875
. 0.0086822509765625
▁Imp 3.376953125
lications 0.19873046875
▁for 0.2308349609375
▁Sur 3.9375
v 1.1796875
ival 0.040496826171875
▁R 1.6748046875
ates 0.045501708984375
▁and 2.55078125
▁Mr 11.5859375
. 0.0220794677734375
▁B 0.018096923828125
' 0.6845703125
s 0.00775146484375
▁Case 0.4794921875
: 0.26171875
<0x0A> 0.00554656982421875
A 0.375244140625
. 0.00811767578125
▁Imp 2.712890625
act 1.23046875
▁on 0.24169921875
▁Sur 0.39013671875
v 0.006134033203125
ival 0.0006432533264160156
▁R 0.5400390625
ates 0.0304107666015625
: 0.11578369140625
<0x0A> 0.015960693359375
The 2.515625
▁introduction 4.05859375
▁of 0.024993896484375
▁imm 0.416748046875
une 0.025360107421875
▁check 0.0070343017578125
point 0.0017328262329101562
▁in 0.00829315185546875
hib 1.0013580322265625e-05
itors 0.0201873779296875
▁and 0.7255859375
▁adj 0.023651123046875
uv 0.001422882080078125
ant 0.0015583038330078125
▁ther 0.03900146484375
ap 0.020843505859375
ies 1.3589859008789062e-05
▁has 0.373779296875
▁significantly 2.3359375
▁en 4.359375
hanced 0.00484466552734375
▁surv 1.2392578125
ival 0.000751495361328125
▁rates 0.1380615234375
▁in 0.86376953125
▁patients 0.32568359375
▁with 0.08251953125
▁advanced 0.62060546875
▁mel 0.2454833984375
an 3.540515899658203e-05
oma 0.0128021240234375
. 0.40966796875
▁These 3.166015625
▁treat 0.75341796875
ments 5.519390106201172e-05
▁offer 4.55078125
▁new 3.748046875
▁hope 0.260986328125
▁for 0.462890625
▁long 6.3984375
- 0.017120361328125
term 0.005153656005859375
▁rem 1.0595703125
ission 0.034210205078125
. 4.91015625
<0x0A> 0.314697265625
B 0.058441162109375
. 0.0008740425109863281
▁Mr 6.0546875
. 0.0168609619140625
▁B 0.006603240966796875
' 0.16552734375
s 0.003814697265625
▁Case 0.09222412109375
: 0.038604736328125
<0x0A> 0.02801513671875
Mr 0.7080078125
. 0.0078582763671875
▁B 0.01666259765625
, 1.248046875
▁diagn 3.998046875
osed 0.0001842975616455078
▁with 0.06524658203125
▁advanced 0.8994140625
▁mel 0.1790771484375
an 3.0279159545898438e-05
oma 0.0005784034729003906
, 1.20703125
▁exempl 7.0234375
ifies 0.016937255859375
▁the 0.22265625
▁potential 1.0546875
▁of 2.8671875
▁imm 0.685546875
une 0.04388427734375
▁check 0.0073699951171875
point 0.0025157928466796875
▁in 0.00736236572265625
hib 2.288818359375e-05
itors 0.0247650146484375
▁to 3.90234375
▁achieve 4.578125
▁rem 3.6015625
ission 0.11981201171875
. 1.7841796875
▁With 4.5
▁p 4.7109375
emb 0.00228118896484375
rol 0.00013625621795654297
iz 0.0005660057067871094
um 0.0013780593872070312
ab 7.474422454833984e-05
▁treatment 3.740234375
, 0.1380615234375
▁his 1.623046875
▁tum 2.056640625
or 0.10577392578125
▁shr 2.359375
inks 4.0859375
▁significantly 1.8291015625
, 0.68603515625
▁leading 2.865234375
▁to 0.0228118896484375
▁increased 5.68359375
▁overall 2.607421875
▁surv 0.0341796875
ival 0.0003504753112792969
▁and 1.4873046875
▁quality 2.609375
▁of 0.0291900634765625
▁life 0.0017175674438476562
. 0.1090087890625
<0x0A> 0.355224609375
Con 3.51171875
clusion 0.174560546875
: 0.300537109375
<0x0A> 4.6328125
The 1.646484375
▁adv 3.388671875
anc 0.630859375
ements 2.753734588623047e-05
▁in 0.2587890625
▁imm 1.3154296875
une 0.387451171875
▁check 0.0295867919921875
point 0.004261016845703125
▁in 0.03204345703125
hib 3.3020973205566406e-05
itors 0.0833740234375
▁and 0.2333984375
▁adj 0.0133209228515625
uv 0.0010042190551757812
ant 0.0006947517395019531
▁ther 0.056732177734375
ap 0.0262451171875
ies 2.3484230041503906e-05
▁have 0.48193359375
▁revolution 4.21484375
ized 0.00330352783203125
▁mel 1.8935546875
an 3.1828880310058594e-05
oma 0.0015935897827148438
▁treatment 0.18603515625
, 1.5498046875
▁offering 1.001953125
▁improved 4.2109375
▁surv 1.2041015625
ival 0.0011949539184570312
▁rates 0.138671875
▁and 0.2744140625
▁the 4.08984375
▁potential 0.287109375
▁for 0.63330078125
▁long 0.406005859375
- 0.00583648681640625
term 0.007434844970703125
▁rem 0.038909912109375
ission 0.0135498046875
. 0.1898193359375
▁These 1.6279296875
▁treat 0.5244140625
ments 6.973743438720703e-05
▁have 0.73388671875
▁shown 2.515625
▁particular 4.80078125
▁effic 4.609375
acy 3.9458274841308594e-05
▁in 0.10736083984375
▁patients 0.5927734375
▁with 0.341796875
▁advanced 0.10406494140625
▁mel 0.5888671875
an 2.8133392333984375e-05
oma 0.0191192626953125
, 0.40380859375
▁while 3.91015625
▁on 6.69921875
going 0.06927490234375
▁research 0.425048828125
▁expl 3.9453125
ores 0.004505157470703125
▁their 0.95556640625
▁benefits 4.10546875
▁for 2.34375
▁patients 0.75146484375
▁at 0.338134765625
▁earlier 4.015625
▁stages 0.042633056640625
. 1.248046875
▁The 2.58984375
▁case 2.451171875
▁of 0.1510009765625
▁Mr 0.02301025390625
. 0.005764007568359375
▁B 0.005809783935546875
▁further 5.16796875
▁demonstr 2.0078125
ates 3.9577484130859375e-05
▁the 0.1490478515625
▁prof 6.71875
ound 0.002208709716796875
▁impact 0.404541015625
▁these 1.4052734375
▁ther 2.416015625
ap 0.00036716461181640625
ies 2.0265579223632812e-06
▁can 0.76953125
▁have 0.0082855224609375
▁on 0.1798095703125
▁patients 1.498046875
' 1.1943359375
▁lives 0.58544921875
, 1.5224609375
▁insp 5.953125
iring 0.0062103271484375
▁hope 0.1773681640625
▁for 0.497314453125
▁a 1.6005859375
▁br 1.4306640625
ighter 2.7060508728027344e-05
▁future 0.03253173828125
▁in 3.8671875
▁mel 1.326171875
an 4.315376281738281e-05
oma 0.0008378028869628906
▁management 4.56640625
. 0.030426025390625
